Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
Is a |
Product containing only bacitracin and neomycin and sulfacetamide in cutaneous dose form (medicinal product form) |
true |
Inferred relationship |
Some |
|
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
Has manufactured dose form |
Cutaneous powder |
true |
Inferred relationship |
Some |
|
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
Plays role |
Antibacterial therapeutic role (role) |
false |
Inferred relationship |
Some |
|
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
Sulfacetamide sodium |
true |
Inferred relationship |
Some |
1 |
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
Sulfacetamide sodium |
true |
Inferred relationship |
Some |
1 |
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
This attribute specifies the numerator unit for the concentration strength of a product. |
mg |
true |
Inferred relationship |
Some |
1 |
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
This attribute specifies the denominator unit for the concentration strength of a product. |
g |
true |
Inferred relationship |
Some |
1 |
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
Bacitracin |
true |
Inferred relationship |
Some |
2 |
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
Bacitracin |
true |
Inferred relationship |
Some |
2 |
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
This attribute specifies the numerator unit for the concentration strength of a product. |
Unit |
true |
Inferred relationship |
Some |
2 |
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
This attribute specifies the denominator unit for the concentration strength of a product. |
g |
true |
Inferred relationship |
Some |
2 |
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
Neomycin sulfate |
true |
Inferred relationship |
Some |
3 |
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
Neomycin sulfate |
true |
Inferred relationship |
Some |
3 |
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
This attribute specifies the numerator unit for the concentration strength of a product. |
mg |
true |
Inferred relationship |
Some |
3 |
|
Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder |
This attribute specifies the denominator unit for the concentration strength of a product. |
g |
true |
Inferred relationship |
Some |
3 |
|